Journal
JOURNAL OF CONTROLLED RELEASE
Volume 343, Issue -, Pages 107-117Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2022.01.026
Keywords
Engineered exosome; LncRNA MEG3; Tumor-targeting therapy; Osteosarcoma
Funding
- National Key Research and Develop-ment Program of China [2016YFC1100100]
- Major Research Plan of National Natural Science Foundation of China [91649204]
Ask authors/readers for more resources
This study demonstrates the potential therapeutic effects of engineered exosomes as targeted delivery vehicles for lncRNA MEG3 in osteosarcoma. The engineered exosomes cRGD-Exo-MEG3 efficiently deliver MEG3 to tumor cells, significantly enhancing its anti-tumor effects.
Exosomes as nanosized membrane vesicles, could targeted deliver therapeutic agents by modification with target ligands. Exosome-derived non-coding RNAs play a vital role in the development of tumors. Previous evidences reveal that long non-coding RNA maternally expressed gene 3 (lncRNA MEG3) has anti-tumor properties. Whereas, the inhibitory effects of exosome-derived lncRNA MEG3 in osteosarcoma (OS) remain largely un-known. In this study, we utilize the engineering technology to combine exosome and lncRNA for tumor-targeting therapy of OS. We elucidated the anti-OS effects of lncRNA MEG3, and then prepared the c(RGDyK)-modified and MEG3-loaded exosomes (cRGD-Exo-MEG3). The engineered exosomes cRGD-Exo-MEG3 could deliver more efficiently to OS cells both in vitro and in vivo. In this way, cRGD-Exo-MEG3 facilitate the anti-OS effects of MEG3 significantly, with the help of enhanced tumor-targeting therapy. This study elucidates that engineered exosomes as targeted lncRNA MEG3 delivery vehicles have potentially therapeutic effects for OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available